期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 23, 期 6, 页码 854-871出版社
WILEY
DOI: 10.1002/ejhf.2190
关键词
Endomyocardial biopsy; Heart failure; Myocarditis; Cardiomyopathy; Amyloidosis; Sarcoidosis; Cardiotoxicity; Heart transplantation; Cardiac tumours
Endomyocardial biopsy (EMB) is an invasive procedure commonly used for monitoring heart transplant rejection and diagnosing various cardiac disorders. Advances in EMB equipment and techniques have improved diagnostic precision. An expert consensus document provides a comprehensive overview on EMB, covering practical approaches, updated indications, revised surveillance plans, the impact of multimodality imaging, and current global clinical practices.
Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important complementary role to the clinical assessment in establishing the diagnosis of diverse cardiac disorders, including myocarditis, cardiomyopathies, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumours. Improvements in EMB equipment and the development of new techniques for the analysis of EMB samples have significantly improved diagnostic precision of EMB. The present document is the result of the Trilateral Cooperation Project between the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America, and the Japanese Heart Failure Society. It represents an expert consensus aiming to provide a comprehensive, up-to-date perspective on EMB, with a focus on the following main issues: (i) an overview of the practical approach to EMB, (ii) an update on indications for EMB, (iii) a revised plan for HTx rejection surveillance, (iv) the impact of multimodality imaging on EMB, and (v) the current clinical practice in the worldwide use of EMB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据